These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 31431050)
1. Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis. Kazmirczak F; Chen KA; Adabag S; von Wald L; Roukoz H; Benditt DG; Okasha O; Farzaneh-Far A; Markowitz J; Nijjar PS; Velangi PS; Bhargava M; Perlman D; Duval S; Akçakaya M; Shenoy C Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007488. PubMed ID: 31431050 [TBL] [Abstract][Full Text] [Related]
2. Applicability of the AHA/ACC/HRS Guideline for Implantable Cardioverter Defibrillator Implantation in Japanese Patients With Cardiac Sarcoidosis. Takenaka S; Kobayashi Y; Nagai T; Kato Y; Komoriyama H; Nagano N; Kamiya K; Konishi T; Sato T; Omote K; Mizuguchi Y; Tada A; Sato T; Iwano H; Kusano K; Ishibashi-Ueda H; Anzai T JACC Clin Electrophysiol; 2021 Nov; 7(11):1410-1418. PubMed ID: 34217654 [TBL] [Abstract][Full Text] [Related]
3. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. Greulich S; Deluigi CC; Gloekler S; Wahl A; Zürn C; Kramer U; Nothnagel D; Bültel H; Schumm J; Grün S; Ong P; Wagner A; Schneider S; Nassenstein K; Gawaz M; Sechtem U; Bruder O; Mahrholdt H JACC Cardiovasc Imaging; 2013 Apr; 6(4):501-11. PubMed ID: 23498675 [TBL] [Abstract][Full Text] [Related]
4. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. Mohsen A; Jimenez A; Hood RE; Dickfeld T; Saliaris A; Shorofsky S; Saba MM J Cardiovasc Electrophysiol; 2014 Feb; 25(2):171-6. PubMed ID: 24433308 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy. Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359 [TBL] [Abstract][Full Text] [Related]
6. The role of ICDs in patients with sarcoidosis-A comprehensive review. Mactaggart S; Ahmed R Curr Probl Cardiol; 2024 May; 49(5):102483. PubMed ID: 38401822 [TBL] [Abstract][Full Text] [Related]
7. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator. Skowasch D; Ringquist S; Nickenig G; Andrié R PLoS One; 2018; 13(3):e0194496. PubMed ID: 29566033 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance. Champ-Rigot L; Gay P; Seita F; Benouda L; Morello R; Pellissier A; Alexandre J; Saloux E; Milliez P J Cardiovasc Magn Reson; 2020 Jun; 22(1):48. PubMed ID: 32580786 [TBL] [Abstract][Full Text] [Related]
9. Incidence of Sudden Cardiac Death and Life-Threatening Arrhythmias in Clinically Manifest Cardiac Sarcoidosis With and Without Current Indications for an Implantable Cardioverter Defibrillator. Nordenswan HK; Pöyhönen P; Lehtonen J; Ekström K; Uusitalo V; Niemelä M; Vihinen T; Kaikkonen K; Haataja P; Kerola T; Rissanen TT; Alatalo A; Pietilä-Effati P; Kupari M Circulation; 2022 Sep; 146(13):964-975. PubMed ID: 36000392 [TBL] [Abstract][Full Text] [Related]
10. The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis. Paz HL; McCormick DJ; Kutalek SP; Patchefsky A Chest; 1994 Nov; 106(5):1603-7. PubMed ID: 7956431 [TBL] [Abstract][Full Text] [Related]
11. Cardiac Magnetic Resonance for Prophylactic Implantable-Cardioverter Defibrillator Therapy in Ischemic Cardiomyopathy: The DERIVATE-ICM International Registry. Pontone G; Guaricci AI; Fusini L; Baggiano A; Guglielmo M; Muscogiuri G; Volpe A; Abete R; Aquaro G; Barison A; Bogaert J; Camastra G; Carigi S; Carrabba N; Casavecchia G; Censi S; Cicala G; De Cecco CN; De Lazzari M; Di Giovine G; Di Roma M; Dobrovie M; Focardi M; Gaibazzi N; Gismondi A; Gravina M; Lanzillo C; Lombardi M; Lorenzoni V; Lozano-Torres J; Martini C; Marzo F; Masi A; Memeo R; Moro C; Nese A; Palumbo A; Pavon AG; Pedrotti P; Marra MP; Pica S; Pradella S; Presicci C; Rabbat MG; Raineri C; Rodriguez-Palomares JF; Sbarbati S; Schoepf UJ; Squeri A; Sverzellati N; Symons R; Tat E; Timpani M; Todiere G; Valentini A; Varga-Szemes A; Masci PG; Schwitter J JACC Cardiovasc Imaging; 2023 Nov; 16(11):1387-1400. PubMed ID: 37227329 [TBL] [Abstract][Full Text] [Related]
12. Myocardial tissue characterization by cardiac magnetic resonance imaging using T1 mapping predicts ventricular arrhythmia in ischemic and non-ischemic cardiomyopathy patients with implantable cardioverter-defibrillators. Chen Z; Sohal M; Voigt T; Sammut E; Tobon-Gomez C; Child N; Jackson T; Shetty A; Bostock J; Cooklin M; O'Neill M; Wright M; Murgatroyd F; Gill J; Carr-White G; Chiribiri A; Schaeffter T; Razavi R; Rinaldi CA Heart Rhythm; 2015 Apr; 12(4):792-801. PubMed ID: 25533585 [TBL] [Abstract][Full Text] [Related]
13. Reversible Cause of Cardiac Arrest and Secondary Prevention Implantable Cardioverter Defibrillators in Patients With Coronary Artery Disease: Value of Complete Revascularization and LGE-CMR. van der Lingen ACJ; Becker MAJ; Kemme MJB; Rijnierse MT; Spoormans EM; Timmer SAJ; van Rossum AC; van Halm VP; Germans T; Allaart CP J Am Heart Assoc; 2021 Apr; 10(8):e019101. PubMed ID: 33821672 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis. Athwal PSS; Chhikara S; Ismail MF; Ismail K; Ogugua FM; Kazmirczak F; Bawaskar PH; Elton AC; Markowitz J; von Wald L; Roukoz H; Bhargava M; Perlman D; Shenoy C JAMA Cardiol; 2022 Oct; 7(10):1057-1066. PubMed ID: 36103165 [TBL] [Abstract][Full Text] [Related]
15. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction. Halliday BP; Gulati A; Ali A; Guha K; Newsome S; Arzanauskaite M; Vassiliou VS; Lota A; Izgi C; Tayal U; Khalique Z; Stirrat C; Auger D; Pareek N; Ismail TF; Rosen SD; Vazir A; Alpendurada F; Gregson J; Frenneaux MP; Cowie MR; Cleland JGF; Cook SA; Pennell DJ; Prasad SK Circulation; 2017 May; 135(22):2106-2115. PubMed ID: 28351901 [TBL] [Abstract][Full Text] [Related]
16. Baseline and Dynamic Risk Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy. Wu KC; Wongvibulsin S; Tao S; Ashikaga H; Stillabower M; Dickfeld TM; Marine JE; Weiss RG; Tomaselli GF; Zeger SL J Am Heart Assoc; 2020 Oct; 9(20):e017002. PubMed ID: 33023350 [TBL] [Abstract][Full Text] [Related]
17. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Kusumoto FM; Bailey KR; Chaouki AS; Deshmukh AJ; Gautam S; Kim RJ; Kramer DB; Lambrakos LK; Nasser NH; Sorajja D J Am Coll Cardiol; 2018 Oct; 72(14):1653-1676. PubMed ID: 29097297 [TBL] [Abstract][Full Text] [Related]
18. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Kusumoto FM; Bailey KR; Chaouki AS; Deshmukh AJ; Gautam S; Kim RJ; Kramer DB; Lambrakos LK; Nasser NH; Sorajja D Heart Rhythm; 2018 Oct; 15(10):e253-e274. PubMed ID: 29097318 [TBL] [Abstract][Full Text] [Related]
19. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Wu KC; Gerstenblith G; Guallar E; Marine JE; Dalal D; Cheng A; Marbán E; Lima JA; Tomaselli GF; Weiss RG Circ Cardiovasc Imaging; 2012 Mar; 5(2):178-86. PubMed ID: 22267750 [TBL] [Abstract][Full Text] [Related]
20. Associations between scar characteristics by cardiac magnetic resonance and changes in left ventricular ejection fraction in primary prevention defibrillator recipients. Zhang Y; Guallar E; Weiss RG; Stillabower M; Gerstenblith G; Tomaselli GF; Wu KC Heart Rhythm; 2016 Aug; 13(8):1661-6. PubMed ID: 27108939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]